Congress backs expanded vaccine funding for world's poorest children
H.Res. 848 — Supporting the role of the United States in helping save the lives of children and protecting the health of people in low-income countries with vaccines and immunization through Gavi, the Vaccine Alliance ("Gavi"). · Filed by Thomas Kean (R-NJ) · 8 cosponsors · Introduced Oct 31, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This House resolution expresses support for continued U.S. funding and participation in Gavi, the Vaccine Alliance, a public-private partnership that delivers vaccines to children in low-income countries. The resolution documents Gavi's track record (1.1 billion children immunized, 18.8 million deaths averted since 2000) and calls on the U.S. government to increase its financial commitment to Gavi's 2026–2030 strategic cycle, particularly for malaria vaccine expansion.
Why we flagged it
This is a non-binding expression of support for continued U.S. participation in and funding of Gavi, a multilateral vaccine-delivery partnership. It contains no legislative mechanism, appropriation, or mandate—only affirmations and encouragements to the executive branch.
What the text implies
- Resolution does not appropriate funds or mandate spending; it is advisory only. Actual budget impact depends on separate appropriations decisions by Congress and executive discretion.
- Support for Gavi indirectly benefits vaccine manufacturers (Pfizer, GSK, Moderna, etc.) by expanding markets and creating predictable demand in low-income countries, though this is a secondary effect of the public health goal.
The full analysis lists 3 implications of this text.
Who stands to gain
vaccine manufacturers (Pfizer, GSK, Moderna, Merck, Serum Institute of India); cold chain equipment suppliers; global health NGOs and implementing partners